| 李小峰,孙新宇,郝光军,马彦娥,苏虎艳,李 婷.腹腔内贝伐珠单抗辅助卵巢癌术后化疗对患者血清AFP、VEGF、TGF-β1、MIF的影响[J].,2022,(2):379-382 |
| 腹腔内贝伐珠单抗辅助卵巢癌术后化疗对患者血清AFP、VEGF、TGF-β1、MIF的影响 |
| The Effect of Chemotherapy with Bevacizumab in the Treatment of Ovarian Cancer after Operation in Patients on Serum AFP, VEGF, TGF-β1 and MIF |
| 投稿时间：2021-05-23 修订日期：2021-06-19 |
| DOI：10.13241/j.cnki.pmb.2022.02.035 |
| 中文关键词: 腹腔灌注 贝伐珠单抗 卵巢癌 化疗 甲胎蛋白 血管内皮生长因子 转化生长因子 巨噬细胞移动抑制因子 |
| 英文关键词: Intraperitoneal perfusion Bevacizumab Ovarian cancer Chemotherapy Alpha fetoprotein Vascular endothelial growth factor Transforming growth factor Macrophage migration inhibitory factor |
| 基金项目: |
|
| 摘要点击次数: 511 |
| 全文下载次数: 316 |
| 中文摘要: |
| 摘要 目的：研究腹腔内贝伐珠单抗辅助卵巢癌术后化疗对患者血清甲胎蛋白（AFP）、血管内皮生长因子（VEGF）、转化生长因子（TGF-β1）、巨噬细胞移动抑制因子（MIF）的影响。方法：选取2019年1月至2021年2月的210例卵巢癌患者。按照随机数表法分为观察组（n=101）和对照组（n=109），对照组采用化疗治疗，观察组在对照组的基础上，采用腹腔内贝伐珠单抗辅助治疗。对比两组治疗效果，血清治疗前后AFP、VEGF、TGF-β1、MIF水平变化，不良反应，随访生存分析结果。结果：治疗后，观察组总有效率显著高于对照组[89.11%（90/101）vs66.05%（72/109）]（P＜0.05）；血清AFP、VEGF、TGF-β1、MIF水平显著低于对照组[（5.19±1.37）ng/mLvs（10.21±2.38）ng/mL，（22.61±4.32）ng/Lvs（35.76±6.34）ng/L，（168.03±20.18）ng/Lvs（203.76±28.69）ng/L，（4.81±1.01）μg/Lvs（12.79±2.50）μg/L]（P<0.05）；两组不良反应对比无显著差异（P>0.05）；平均生存时间、2年生存率显著高于对照组[（19.23±1.36）月vs（19.23±1.36）月，79.21%（80/101）vs28.44%（31/109）]（P<0.05），局部复发与转移显著低于对照组[9.90%（10/101）vs13.76%（15/109）]（P<0.05）。结论：腹腔内贝伐珠单抗辅助卵巢癌术后化疗可有效改善患者的临床症状，缓解疾病发展，降低血清AFP、VEGF、TGF-β1、MIF水平，提高患者生存预后。 |
| 英文摘要: |
| ABSTRACT Objective: To study the effect of chemotherapy with bevacizumab in the treatment of ovarian cancer after operation The influence on serum AFP, VEGF, TGF-β1 and MIF. Methods: 120 Ovarian cancer patients who received therapy from January 2019 to February 2020 in our hospital were selected as research objects. According to random number table, those patients were divided into the observation group (n=101) and the control group (n=109). The control group was treated with chemotherapy. The observation group was treated with bevacizumab on the basis of the control group. The results of the two groups were compared, AFP, VEGF and TGF before and after serum treatment-β1. MIF level changes, adverse reactions, follow-up survival analysis results. Results: After treatment, The total effective rate of observation group was significantly higher than that of control group[89.11%（90/101）vs66.05%（72/109）](P＜0.05). Serum AFP, VEGF, TGF- β 1. MIF level was significantly lower than that of the control group[（5.19±1.37）ng/mLvs（10.21±2.38）ng/mL,（22.61±4.32）ng/Lvs（35.76±6.34）ng/L,（168.03±20.18）ng/Lvs（203.76±28.69）ng/L, （4.81±1.01）μg/Lvs（12.79±2.50）μg/L]（P<0.05）. There was no significant difference in adverse reactions between the two groups（P>0.05）. The average survival time and 2-year survival rate of the treatment group were significantly higher than those of the control group [（19.23±1.36）month vs（19.23±1.36）month, 79.21%（80/101）vs28.44%（31/109）]（P<0.05）.Local recurrence and metastasis were significantly lower than those in the control group（P<0.05）. Conclusion: Chemotherapy with bevacizumab in abdominal cavity can improve the clinical symptoms of patients with ovarian cancer after operation，alleviating disease development, the serum levels of AFP, VEGF, TGF-β1 and MIF were decreased, improve the survival and prognosis of patients. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
